Evidence map›Paper›PMID 30345459›Full record

ArticlePsychopharmacology2019

The synthetic cathinones, butylone and pentylone, are stimulants that act as dopamine transporter blockers but 5-HT transporter substrates.

Kusumika Saha, Yang Li, Marion Holy, Kurt R Lehner, Mohammad O Bukhari, John S Partilla, Walter Sandtner, Harald H Sitte, Michael H Baumann

Abstract read
In one paragraph

Article in Psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review.International journal of molecular sciences · 2023
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Kusumika SahaCenter for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Waehringerstrasse 13A, 1090, Vienna, Austria.
Yang LiCenter for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Waehringerstrasse 13A, 1090, Vienna, Austria.
Marion HolyCenter for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Waehringerstrasse 13A, 1090, Vienna, Austria.
Kurt R LehnerDesigner Drug Research Unit (DDRU), Intramural Research Program (IRP), NIDA, NIH, DHHS, 333 Cassell Drive, Suite 4400, Baltimore, MD, 21224, USA.
Mohammad O BukhariDesigner Drug Research Unit (DDRU), Intramural Research Program (IRP), NIDA, NIH, DHHS, 333 Cassell Drive, Suite 4400, Baltimore, MD, 21224, USA.
John S PartillaDesigner Drug Research Unit (DDRU), Intramural Research Program (IRP), NIDA, NIH, DHHS, 333 Cassell Drive, Suite 4400, Baltimore, MD, 21224, USA.
Walter SandtnerCenter for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Waehringerstrasse 13A, 1090, Vienna, Austria.
Harald H SitteCenter for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna, Waehringerstrasse 13A, 1090, Vienna, Austria.
Michael H BaumannDesigner Drug Research Unit (DDRU), Intramural Research Program (IRP), NIDA, NIH, DHHS, 333 Cassell Drive, Suite 4400, Baltimore, MD, 21224, USA. mbaumann@mail.nih.gov.
Medical University of Vienna · ATUnited States Department of Health and Human Services · USCentre National de la Recherche Scientifique · FRJohns Hopkins Hospital · USUniversity of Pittsburgh Medical Center · US

Funding

Studies on MDMA and Related CompoundsZIADA000523 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI BAUMANN, MICHAEL · 2009 to 2025
$16.4M
Preclinical medication development for stimulant use disorderZIADA000522 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI BAUMANN, MICHAEL · 2009 to 2025
$8.9M
IMPROVING HEALTH CARE UTILIZATION IN HIV+ DRUG USERSK23DA000523 · NIDA · JOHNS HOPKINS UNIVERSITY · PI GEBO, KELLY A · 2001 to 2005
$794k
Studies on MDMA and Related CompoundsZ01DA000523 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI ROTHMAN, RICHARD · 2008 to 2008
$199k
Austrian Science Fund FWF W 1232Intramural NIH HHS Z01 DA000523Intramural NIH HHS ZIA DA000523NIDA NIH HHS DA 00523NIDA NIH HHS K23 DA000523
6 · The paper itself

Abstract

rationaleSynthetic cathinones continue to emerge in recreational drug markets worldwide. 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) and 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) are derivatives of the cathinone compound, 1-(1,3-benzodioxol-5-yl)-2-(methylamino)propan-1-one (methylone), that are being detected in drug products and human casework.

objectivesThe purpose of the present study was to examine the neuropharmacology of butylone and pentylone using in vitro and in vivo methods.

methodsIn vitro uptake and release assays were carried out in rat brain synaptosomes and in cells expressing human dopamine transporters (DAT) and 5-HT transporters (SERT). In vivo microdialysis was performed in the nucleus accumbens of conscious rats to assess drug-induced changes in neurochemistry.

resultsButylone and pentylone were efficacious uptake blockers at DAT and SERT, though pentylone was more DAT-selective. Both drugs acted as transporter substrates that evoked release of [

conclusionsOur data demonstrate that increasing the α-carbon chain length of methylone creates "hybrid" transporter compounds which act as DAT blockers but SERT substrates. Nevertheless, butylone and pentylone elevate extracellular dopamine and stimulate motor activity, suggesting both drugs possess significant risk for abuse.

Indexed as

3,4-MethylenedioxyamphetamineAlkaloidsAmphetaminesAnimalsCentral Nervous System StimulantsDopamine AntagonistsDopamine Plasma Membrane Transport ProteinsDose-Response Relationship, DrugHEK293 CellsHumansMaleMethamphetamineNucleus AccumbensRatsRats, Sprague-DawleySynaptosomes2-methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one3,4-MethylenedioxyamphetamineAlkaloidsAmphetaminescathinoneCentral Nervous System StimulantsDopamine AntagonistsDopamine Plasma Membrane Transport ProteinsMethamphetaminemethylonepentyloneSynthetic Drugs5-HTCathinoneDopamineMicrodialysisNeurochemistryTransporter

Identifiers

PMID30345459
PMCPMC6476708
OpenAlexW2897051077

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.